本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
ONTARIO, Calif., March 13, 2026 /PRNewswire/ -- Nature's Miracle Holding Inc. ("Nature's Miracle" or the "Company") (OTCQB: NMHI), a leader in controlled environment agriculture, today announced that it is setting up an investor hotline at 1-800-816-3223. This replaces a previously provided number. Or email inquiries to info@nature-miracle.com. About Nature's Miracle Holding Inc. Nature's Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing equipment and services to the Controlled Environment Agriculture ("CEA") industry, including vertical farming in North America. Through its two wholly-owned subsidiaries, Visiontech Group, Inc. and Hydroman, Inc., Nature's Miracle provides grow lights and hydroponic products to hundreds of indoor growers. The Company also maintains a robust pipeline to build commercial-scale greenhouses to meet the growing demand for fresh, local produce in North America. Important Information About Press Release This press release includes information about the MOU. Other than specific provisions in the MOU, the MOU deal points, including the structure of the acquisition and the consideration to be offered, among other things, are not binding. This press release is intended to show the willingness of the parties to fulfill plans that complement their businesses. A transaction is final only upon the signing of a definitive agreement. This press release contains a phone number for the Company but may not be available 24 hours a day, have limited personnel handling such communications. The Company reserves the right not to reply to harassment type messages and threats. This press release does not contain all the information that should be considered concerning the stock of Nature's Miracle, its warrants, and its related businesses. The press release is not intended to form the basis of any investment decision or any other decision in respect to the securities of Nature's Miracle. More information can be obtained by writing directly to Nature's Miracle Holding Inc., 3281 E. Guasti Rd.#175., Ontario, CA 91761, attention Investor Information. Forward-looking Statements Except for historical information contained herein, this press release contains certain "forward-looking statements" within the meaning of the federal U.S. securities laws with respect to the MOU and business of Nature's Miracle; other future references such as the anticipated synergies resulting from the transactions contemplated by the MOU, the services and markets of Nature's Miracle, our expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. These forward-looking statements generally are identified by words such as "anticipate," "believe," "expect," "may," "could," "will," "potential," "intend," "estimate," "should," "plan," "predict," or the negative or other variations of such statements, reflect our management's current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the business and revenue prospects of Nature's Miracle may not materialize which may adversely affect the price of Nature's Miracle's securities; (ii) the occurrence of any unforeseen event that would impact continued listing of Nature's Miracle's securities on the Nasdaq exchange; (iii) changes in the competitive industries in which Nature's Miracle operates, variations in operating performance across competitors, changes in laws and regulations affecting Nature's Miracle's business and changes in the combined capital structure; (iv) the ability to implement business plans, forecasts and other expectations after the completion of the proposed transactions contemplated by the MOU; (v) the risk of downturns in the market and Nature's Miracle's industry including, but not limited to market prices of indoor grower's produce, transportation costs, competition with outdoor growers and demand in the consumer marketplace. For additional details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our prospectus/proxy statement included in our Registration Statement on Form S-4 on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and neither Nature's Miracle assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Nature's Miracle does not give any assurance that the Company will achieve its expectations. Non-solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential business combination or any other matter and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Nature's Miracle, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.
STOCKHOLM, March 13, 2026 /PRNewswire/ -- On March 12, 2026, Ericsson (NASDAQ:ERIC) filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (SEC). The Annual Report is available on Ericsson's website at https://www.ericsson.com/en/investors. Shareholders may request a hard copy of the Annual Report by contacting the company. NOTES TO EDITORS: FOLLOW US: Subscribe to Ericsson press releases hereSubscribe to Ericsson blog posts herehttps://twitter.com/ericssonhttps://www.facebook.com/ericssonhttps://www.linkedin.com/company/ericsson MORE INFORMATION AT:Ericsson Newsroommedia.relations@ericsson.com (+46 10 719 69 92)investor.relations@ericsson.com (+46 10 719 00 00) ABOUT ERICSSON:Ericsson's high-performing networks provide connectivity for billions of people every day. For 150 years, we've been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com This information was brought to you by Cision http://news.cision.com https://news.cision.com/ericsson/r/ericsson-annual-report-on-form-20-f-filed-with-the-sec,c4317867 The following files are available for download: https://mb.cision.com/Main/15448/4317867/3969640.pdf Ericsson Annual Report on Form 20-F filed with the SEC
World's largest CSD project in production with phase two.Delivers instant value to B3 and its members. STOCKHOLM, March 12, 2026 /PRNewswire/ -- B3, the Brazilian marketplace operator, has successfully completed phase two of its new central securities depository (CSD) system, built on VeriSafe® technology from the global independent market infrastructure provider Vermiculus. The new elastically scalable CSD system is the result of one of the largest CSD transformation projects in the world. For the second year in a row, Vermiculus and B3 have successfully brought a major phase of this program into production, delivering significant market value to B3's operations as well as new features used daily by its market participants. With the new platform, B3 is positioned to support the growth of the Brazilian capital market over the next decades, both in terms of new products and services, and the increasing number of investors, assets, issuers, and transactions processed. The VeriSafe system is now configured to support the full range of complex transactional rules required by a modern CSD. This includes processing of, for example, settlement transactions, participant transfers, deposits, withdrawals, and IPOs. In addition, VeriSafe supports the creation and redemption processes for all Brazilian certificate types, including ETFs, depository receipts and fractional shares. VeriSafe is designed to handle extreme volume requirements and to support the storage and processing of several hundred million accounts, investors and daily transactions. The system's microservice-based architecture enables elastic scalability, allowing the platform to efficiently scale further as the market grows. It also allows B3 to rapidly introduce new products and services with significantly shorter time-to-market, while maintaining high levels of operational resilience and stability. Viviane Basso, B3's Chief Operating Officer – Issuers, Depository and OTC: "The new CSD gives us a robust, scalable and efficient platform that prepares us for the future. We are now prepared to handle growth of up to ten times today's levels, while continuously expanding our offering to customers, without disrupting ongoing operations." The CSD transformation has been delivered through frequent releases and agile methodology, ensuring transparency, continuous improvement, and minimal operational risk. Henrik Rouet-Leduc, CSD project manager at Vermiculus: "This project is setting a new standard for how fast and efficient major CSD transformations can be achieved. We are demonstrating how, through close collaboration, a superior delivery model, unmatched industry expertise and the world's most modern CSD platform, we can gradually replace one of the world's most complex CSD systems. All while staying on schedule, and on promise, while continuously delivering tangible value to both B3 and its customers." Taraneh Derayati, CEO of Vermiculus: "As an independent technology provider, we can focus entirely on enabling our customers to succeed on their own terms, with technology that is truly built around their needs on a modern product suite. It has been very rewarding to work closely with B3 and to deliver a system that delivers value to their clients directly and meets their exceptional demands." Vermiculus and B3 are swiftly moving forward with the third and final phase of the transformation, which will replace B3's existing corporate actions module. This next step will further extend the system's capabilities to handle high volumes of complex corporate action calculation, simulation, and processing. About B3 S.A. B3 S.A. (B3SA3) is one of the main financial market infrastructure companies in the world and one of the largest in terms of market capitalization among global leaders in the exchange industry. B3 connects, develops and enables the financial and capital market and, together with customers and society, boosts Brazil's growth. It trades in stock exchange and OTC environments and offers products and services to the financing chain. Headquartered in São Paulo and with offices in London, Chicago, Singapore and Shanghai, B3 performs important functions in the market by promoting best practices in corporate governance, risk management and sustainability. B3 MEDIA RELATIONSimprensa@b3.com.br About Vermiculus Vermiculus Financial Technology AB provides best-in-class trading, clearing, and CSD solutions to market participants around the world. Vermiculus' solutions are the first to bring state-of-the-art advances in dynamic microservice architecture together with vast experience in clearing house, exchange, and CSD business requirements. The company started its operation in 2020 and is founded by industry experts with the incentive to revolutionize the technology of exchanges, clearing houses, and CSDs. With its headquarters in Stockholm, Sweden, Vermiculus consists of hand-picked teams, trained to deliver mission-critical solutions. With decades of accumulated knowledge and expertise, the team has previously completed 5+ projects for the world's largest exchanges, clearing houses, and CSDs. Media contactAmelie Hedenstierna, Marketing & Communications+46736222454Amelie.hedenstierna@vermiculus.se This information was brought to you by Cision http://news.cision.com https://news.cision.com/vermiculusft/r/b3-reaches-major-milestone-with-new-cloud-native-csd-system-from-vermiculus,c4320432 The following files are available for download: https://news.cision.com/vermiculusft/i/taraneh-derayati--ceo-of-vermiculus,c3518971 Taraneh Derayati, CEO of Vermiculus https://news.cision.com/vermiculusft/i/henrik-rouet-leduc-vermiculus,c3518974 Henrik Rouet-Leduc Vermiculus
Pioneering NAD and Mitochondrial Optimization Company Taps Rebelution E-Commerce's Infrastructure to Deliver Affordable, Ground-Zero Natural Health and Wellness to Everyone. CHICAGO, March 12, 2026 /PRNewswire/ -- Rebelution, a full-service e-commerce agency and operational infrastructure provider powered by Growvana, today announced a strategic partnership with Best 365 Labs, a wholly owned subsidiary of Bioscience Health Innovations (OTC: BHIC), to lead the company's Amazon operations as Best 365 Labs accelerates its mission to make science-backed cellular health accessible and affordable for everyone. Best 365 Labs is not just another supplement brand. Built around its proprietary MODS Max™ (Mineral Oxide Delivery System) platform, the company has solved one of the most persistent challenges in nutritional science: bioavailability. Where conventional oral supplements deliver just 10–20% of their active ingredients, MODS Max achieves enhanced bioavailability through a patented mechanism that transiently opens tight junctions in mucosal membranes— enabling the body to absorb what it takes. This breakthrough spans sublingual, oral, nasal, and topical formats across a portfolio of 30 patent-pending formulations targeting NAD restoration, hormonal optimization, sleep architecture, tissue repair, metabolic health, and longevity. The company refers to this as "affordable ground-zero natural health and wellness"— the principle that total cellular health should begin at the biological root cause, not mask symptoms, and should be accessible to everyone regardless of income or zip code. By dramatically improving how the body absorbs nutrients, peptides, and bioactive compounds, Best 365 Labs has created a new category of high-performance supplements at price points that put total cellular health within reach for everyday consumers. Best 365 Labs is a wholly owned subsidiary of Bioscience Health Innovations, publicly traded as BHIC on the OTC market. The company is actively pursuing a major exchange uplist as it scales operations and expands its retail footprint nationwide. Through this partnership, Rebelution will own Best 365 Lab's full Amazon commercialization strategy— from product detail page optimization and brand storefront development to conversion-focused content execution and marketplace growth. Growvana's platform infrastructure will power the operational backbone, enabling the retail channel scalability and supply chain discipline that a high-growth, publicly traded company demands. Together, the engagement represents a complete modernization of Best 365 Labs' Amazon presence—built to institutional standards and designed to grow alongside BHIC's trajectory toward a major exchange uplist. "We are excited for what Rebelution and Growvana can help us accomplish through their Amazon prowess and AI-driven technology. They are the option we have been looking for on the Amazon front and gaining traction and education on the numerous innovations we have and are releasing. Our breakthroughs in NAD optimization and total cellular health — powered by MODS Max — have opened up what we call affordable ground-zero natural health and wellness, and this partnership gives us the infrastructure to bring those innovations to millions of consumers who deserve access to real science-backed solutions." — Darren Lopez, CEO, Best 365 Labs / Bioscience Health Innovations (OTC: BHIC) "Best 365 Labs is building something exceptional — a health and wellness brand backed by real science and a disciplined growth strategy aimed at the public markets. Powered by Growvana's platform and operated by Rebelution's infrastructure, we are bringing our full operational capability to this partnership. Our focus is on centralizing Amazon ownership, driving content excellence, and creating the kind of scalable, compliant infrastructure that institutional investors and retail ecosystems demand. We are proud to support Best 365 Labs at this pivotal stage of its growth." — Melonie Carnegie, CEO, Rebelution With over 5,000 patient-uses and zero serious adverse events reported, MODS Max has demonstrated both safety and efficacy across a wide range of applications — from NAD/mitochondrial restoration and natural testosterone optimization to sleep support, tissue repair, and metabolic health. As BHIC prepares for a major exchange uplist, this Amazon partnership represents a critical step in scaling consumer access and building the retail infrastructure to support that transition. About Best 365 Labs Best 365 Labs, a wholly owned subsidiary of Bioscience Health Innovations (OTC: BHIC), is a health and wellness innovation company on a mission to help people live healthier, longer, and more vital lives through mitochondrial and metabolic optimization. The company's portfolio features 30 patent-pending formulations powered by MODS Max™, a proprietary mineral oxide delivery system that achieves higher bioavailability. Best 365 Labs is pioneering affordable ground-zero natural health and wellness, making advanced cellular health science accessible to everyone. BHIC is currently traded on the OTC market and is actively pursuing a major exchange uplist (OTC: BHIC). For more information, visit best365labs.com. About Rebelution Rebelution is a full-service e-commerce agency and operational infrastructure provider managing more than 2 million ASINs with AI-driven technology that helps brands dominate Amazon, Walmart, and Target. As the operational engine behind the Growvana platform, Rebelution delivers capital efficiency, advanced logistics, and end-to-end channel management for high-growth brands across e-commerce and traditional retail. For more information, visit joinrebelution.com. About Growvana Growvana is an advanced omnichannel distribution platform that powers brand acceleration through sophisticated technology and multi-channel integration across Amazon, Walmart, Target, and brick-and-mortar retail. For more information, visit growvana.com.
TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 4, 2026 /PRNewswire/ -- Cellebrite (Nasdaq: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). Cellebrite's 2025 Annual Report on Form 20-F is available on the investor relations section of its website at https://investors.cellebrite.com/financial-information/sec-filings and on the SEC's website at www.sec.gov. Shareholders may request a hard copy of the 2025 Annual Report on Form 20-F, free of charge, by contacting the Company at investors@cellebrite.com. References to Websites and Social Media PlatformsReferences to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About CellebriteCellebrite's (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite's AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite's technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com. Investor RelationsAndrew KramerVice President, Investor Relationsinvestors@cellebrite.com+1 973.206.7760 MediaVictor CooperSr. Director of Corporate Communications + Content OperationsVictor.cooper@cellebrite.com+1 404.804.5910
SHANGHAI, March 4, 2026 /PRNewswire/ -- MaxsMaking Inc. (Nasdaq: MAMK) ("MaxsMaking" or the "Company"), a manufacturer of customized consumer goods with a focus on advanced technology and innovation, today announced its financial results for the fiscal year ended October 31, 2025. Mr. Xiaozhong Lin, Chairman and Chief Executive Officer of MaxsMaking, commented: "The fiscal year 2025 represented a period of business adjustment for our Company amid heightened uncertainty and intensifying competition. Facing a weak and volatile overseas market, we adopted a business strategy to help us maintain stable revenue growth while improving the efficiency of resource allocation for sales and market development. "In the highly competitive domestic market, we strengthened our sales initiatives to expand our customer base. We implemented a volume-driven strategy supported by penetration pricing and new customer acquisition through relationship-based referrals. These efforts contributed to a 36.33% year-over-year increase in revenue. Importantly, this growth helped offset the temporary slowdown in our overseas business and broadened and diversified our future customer base. "At the same time, we remained committed to innovation, increasing our research and development ("R&D") spending by 16.38%. This investment reflects our long-term focus on product enhancement and on building sustainable differentiation in the customized consumer goods market. "Although our profits and margins were temporarily affected by the volume-driven strategy, we believe our business model remains resilient and scalable. Today, we operate with a more diversified market presence, a broader customer base, and an expanding product portfolio. We believe all of these will support our future growth. "It is also worth noting that our initial public offering (the "IPO") on the Nasdaq in July 2025 provided us access to additional capital and enhanced our presence in global markets. Despite ongoing external challenges and volatility in international trade, we believe our successful IPO has elevated us to a broader platform, enabling us to establish relationships with larger industry players, benefit from collaboration with more elite partners, and embrace further opportunities to support our operations and planned expansion. "Looking ahead, we believe our strategy and execution will provide a foundation for long-term value. As current disruptions and uncertainties evolve, we expect to continue adapting to market conditions and pursuing growth opportunities as they arise." Fiscal Year 2025 Financial Summary Revenue was $29.22 million in fiscal year 2025, representing an increase of 36.33% compared to $21.43 million in fiscal year 2024. Gross profit was $2.62 million in fiscal year 2025, compared to $3.97 million in fiscal year 2024. Gross profit margin was 8.95% in fiscal year 2025, compared to 18.52% in fiscal year 2024. Net income was $0.02 million in fiscal year 2025, compared to $1.88 million in fiscal year 2024. Basic and diluted earnings per A share and B share were $0.00 in fiscal year 2025, compared to $0.25 in fiscal year 2024. Fiscal Year 2025 Financial Results Revenue Revenue was $29.22 million in fiscal year 2025, representing an increase of 36.33% from $21.43 million in fiscal year 2024. The increase was primarily attributable to an increase in sales in mainland China of approximately $9.36 million, or 54.13%, partially offset by a decrease of approximately $1.19 million in sales in Asia (excluding mainland China) and a decrease of $0.54 million in sales in Europe. The increase in sales in mainland China was primarily attributed to: (i) the Company's intensified sales efforts in the domestic market, such as offering promotions and active participation in domestic shopping festivals, expansion of its customer base, and implementation of a high-volume, lower-margin sales strategy, which resulted in increased domestic sales revenue; and (ii) the addition of new major clients through referral by the Company's management. The decrease in sales in overseas markets was mainly due to uncertainties in overseas markets, where customers' demand and consumption prospects remained relatively weak. For the Fiscal Year Ended October 31, 2025 For the Fiscal Year Ended October 31, 2024 Change Country/Region Sales Amount As % of Sales Sales Amount As % of Sales Amount % Mainland China $ 26,643,100 91.18 % $ 17,285,726 80.65 % $ 9,357,374 54.13 % Asia (excluding mainland China) 810,415 2.77 % 1,998,048 9.32 % (1,187,633) (59.44) % North America 345,277 1.18 % 276,746 1.29 % 68,530 24.76 % Europe 1,266,824 4.34 % 1,806,989 8.43 % (540,165) (29.89) % Oceania 41,158 0.14 % 16,650 0.08 % 24,508 147.19 % South America 62,948 0.22 % 30,170 0.14 % 32,778 108.64 % Africa 51,124 0.17 % 19,771 0.09 % 31,354 158.59 % Total 29,220,846 100.00 % $ 21,434,100 100.00 % $ 7,786,746 36.33 % Cost of Revenue Cost of revenue was $26.61 million in fiscal year 2025, representing an increase of 52.34% from $17.46 million in fiscal year 2024. The increase was due to higher domestic sales volume, which has lower gross profit margins, resulting in cost growth outpacing revenue growth. Gross Profit and Gross Profit Margin Gross profit was $2.62 million in fiscal year 2025, compared to $3.97 million in fiscal year 2024. Gross profit margin was 8.95% in fiscal year 2025, compared to 18.52% in fiscal year 2024. The decline in gross profit margin was primarily attributable to a decrease in overseas sales, which historically generate higher margins. As overseas sales declined, the Company's overall gross profit decreased. In response, the Company intensified its sales efforts in the domestic market and adopted a lower-price, higher-volume strategy, which increased domestic sales but carried a lower margin and further compressed the Company's overall gross profit margin. Operating Expenses Operating expenses were $2.51 million in fiscal year 2025, representing an increase of 42.25% from $1.77 million in fiscal year 2024. Selling expenses were $0.46 million in fiscal year 2025, representing a decrease of 23.76% from $0.61 million in fiscal year 2024. The decrease was mainly due to lower salary expenses resulting from a reduction in headcount, and a decrease in freight expenses. General and administrative expenses were $1.40 million in fiscal year 2025, representing an increase of 132.97% from $0.60 million in fiscal year 2024. The increase was mainly due to (i) an increase in accounts receivable allowance of approximately $0.17 million; and (ii) an increase in professional fees of $0.44 million in connection with the Company's IPO in July 2025. Research and development expenses were $0.65 million in fiscal year 2025, representing an increase of 16.38% from $0.56 million in fiscal year 2024. The increase was primarily attributable to an increase in salaries of the Company's R&D personnel. Net Income Net income was $0.02 million in fiscal year 2025, compared to $1.88 million in fiscal year 2024. Basic and Diluted Earnings per Share Basic and diluted earnings per A share and B share were $0.00 in fiscal year 2025, compared to $0.25 in fiscal year 2024. Financial Condition As of October 31, 2025, the Company had cash of $0.12 million, compared to $0.18 million as of October 31, 2024. Net cash used in operating activities was $5.29 million in fiscal year 2025, compared to $3.04 million in fiscal year 2024. Net cash used in investing activities was $56,877 in fiscal year 2025, compared to $18,514 in fiscal year 2024. Net cash provided by financing activities was $5.30 million in fiscal year 2025, compared to $3.10 million in fiscal year 2024. About MaxsMaking Inc. Founded in 2007 and headquartered in Shanghai, MaxsMaking Inc. specializes in customized consumer goods with a focus on advanced technology and innovation. With production facilities in China's Zhejiang and Henan provinces, the Company integrates digital production, software development, product design, brand management, online sales and international trade to deliver small-batch textile customization services. Its products include backpacks, shopping bags, aprons, and other promotional items. Using sustainable materials and proprietary order management technologies, MaxsMaking delivers high-quality, cost-effective products while emphasizing environmental protection and social responsibility. For more information, please visit the Company's website: https://ir.maxsmaking.com/. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2025 and other filings with the U.S. Securities and Exchange Commission. For more information, please contact: MaxsMaking Inc.Investor RelationsEmail: ir@maxsmaking.com Ascent Investor Relations LLCTina XiaoPhone: +1-646-932-7242Email: investors@ascent-ir.com MAXSMAKING INC. CONSOLIDATED BALANCE SHEETS FOR THE FISCAL YEARS ENDED OCTOBER 31, 2025 AND 2024 IN U.S. DOLLARS, EXCEPT SHARE DATA October 31,2025 October 31,2024 ASSETS Current Assets Cash $ 122,381 $ 176,236 Accounts receivable, net 9,877,030 6,188,992 Due from related parties 36,815 — Inventories 6,504,761 2,633,615 Other receivables and other current assets 5,003,667 7,452,317 Total current assets 21,544,654 16,451,160 Non-Current Assets Plant and equipment, net 153,271 119,125 Intangible assets, net 6,447 7,433 Right-of-use assets, net 71,482 86,441 Deferred tax assets 66,383 24,538 Deferred offering cost - 986,206 Total non-current assets 297,583 1,223,743 Total Assets $ 21,842,237 $ 17,674,903 LIABILITIES AND EQUITY Current Liabilities Short-term loans $ 1,954,007 $ 2,785,965 Accounts payable 3,243,451 2,127,623 Contract liability 449,306 512,859 Income tax payable 952,041 859,194 Other payables and accrued liabilities 259,345 867,249 Due to related parties - 149,757 Lease liabilities-current 13,145 47,895 Current portion of long-term loan 22,573 - Total current liabilities 6,893,868 7,350,542 Non-Current Liabilities Lease liabilities-non current 57,841 — Non-current portion of long-term loans 2,278,162 2,058,651 Total non-current liabilities 2,336,003 2,058,651 Total liabilities 9,229,871 9,409,193 COMMITMENTS AND CONTINGENCIES (NOTE 17) Equity A Shares (US$ 0.01 par value; 9,200,000 A Shares authorized, 7,575,000 A Shares issued and outstanding as of October 31, 2024 and October 31, 2023) 92,000 75,750 B Shares (US$0.01 par value; 7,425,000 B Shares authorized, 7,425,000 B Shares issued and outstanding as of October 31, 2024 and October 31, 2023) 74,250 74,250 Additional paid-in capital 5,972,110 1,712,492 Statutory surplus reserve 788,123 705,396 Retained earnings 5,726,180 5,806,881 Accumulated other comprehensive loss (368,876) (421,542) Total MaxsMaking Inc.'s Equity 12,283,787 7,953,227 Non-Controlling Interests 328,579 312,483 Total equity 12,612,366 8,265,710 Total Liabilities and Equity $ 21,842,237 $ 17,674,903 MAXSMAKING INC. CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME FOR THE FISCAL YEARS ENDED OCTOBER 31, 2025, 2024 and 2023 IN U.S. DOLLARS, EXCEPT SHARE DATA For The Fiscal Years Ended October 31, 2025 2024 2023 Revenues $ 29,220,846 $ 21,434,100 $ 26,260,268 Cost of revenues (26,605,003) (17,463,856) (22,048,972) Gross profit 2,615,843 3,970,244 4,211,296 Operating expenses: Sales and marketing expenses (462,285) (606,352) (490,221) General and administrative expenses (1,399,356) (600,660) (571,407) Research and development expenses (650,629) (559,048) (740,800) Total operating expenses (2,512,270) (1,766,060) (1,802,428) Income from operations 103,573 2,204,184 2,408,868 Other (expenses) income, net Interest expenses (159,166) (151,335) (69,572) Interest income 223 548 1,158 Other income 85,113 95,767 87,399 Exchange gain (loss) 72,406 17,344 (2,106) Other expenses (16,593) (16,839) (140,029) Income before income tax provision 85,556 2,149,669 2,285,718 Income tax expense (67,434) (269,003) (307,441) Net income $ 18,122 $ 1,880,666 $ 1,978,277 Less: Net income attributable to non-controlling interest 16,096 67,496 69,006 Net income attributable to MaxsMaking Inc. 2,026 1,813,170 1,909,271 Other comprehensive income Foreign currency translation adjustment 52,666 36,714 (39,443) Comprehensive income $ 70,788 $ 1,917,380 $ 1,938,834 Less: comprehensive income (loss) attributable to non-controlling interests 832 (839) (7,775) Comprehensive (loss) income attributable to MaxsMaking Inc. $ 69,956 $ 1,918,219 $ 1,946,609 Weighted Average A Shares Outstanding – Basic and Diluted 8,092,857 7,575,000 7,575,000 Weighted Average B Shares Outstanding – Basic and Diluted 7,425,000 7,425,000 7,425,000 Earnings per A Share – basic and diluted $ 0.00 $ 0.25 $ 0.26 Earnings per B Share – basic and diluted $ 0.00 $ 0.25 $ 0.27 MAXSMAKING INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE FISCAL YEARS ENDED OCTOBER 31, 2025, 2024 and 2023 IN U.S. DOLLARS, EXCEPT SHARE DATA For The Fiscal Years Ended October 31, 2025 2024 2023 Cash Flows from Operating Activities: Net income $ 18,122 $ 1,880,666 $ 1,978,277 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation of plant and equipment 30,573 28,548 22,638 Allowance (Reversal of allowance) for expected credit loss of accounts receivable 173,564 17,064 (23,422) Amortization of right-of-use assets 138,080 179,858 189,311 Amortization of intangible assets 1,014 1,021 1,032 Accounts receivable (3,791,371) 168,688 1,895,868 Inventories (3,817,383) (412,235) 56,562 Other receivables and other current assets 2,240,000 (4,142,973) (1,397,468) Amount due from related party (36,433) 422 (426) Deferred tax assets (41,284) (19,841) (2,575) Operating lease-right of use assets (122,830) (45,928) — Deferred offering cost (332,851) (905,452) (273,346) Other non-current assets — 196,834 178,786 Accounts payable 1,091,381 1,094,933 (4,279,114) Income tax payable 87,446 283,245 87,502 Contract liability 134,680 (328,693) 164,529 Other payables and accrued liabilities (928,045) 13,537 (100,599) Lease liabilities 22,604 (327,396) (167,614) Amount due to related party (153,012) (720,729) 1,070,112 Net cash used in operating activities (5,285,745) (3,038,431) (599,947) Cash Flows from Investing Activities: Purchases of plant and equipment (56,877) (18,514) (73,646) Collection from loans to third parties — — 810,250 Net cash (used in)generated by investing activities (56,877) (18,514) 736,604 Cash Flows from Financing Activities: Proceeds from issuance of ordinary shares upon the completion of IPO 5,594,926 — — Capital contributions — 787,266 — Proceeds from third party loans 184,559 260,101 71,055 Proceeds from bank borrowings 3,036,036 4,611,529 1,406,889 Repayments of third party loans (325,058) (745,156) — Repayment of bank borrowings (3,191,570) (1,813,680) (1,806,122) Net cash provided by(used in) financing activities 5,298,893 3,100,060 (328,178) Effect of Exchange Rate Changes on Cash (10,126) 971 3,715 Net (Decrease) Increase in cash (53,855) 44,086 (187,806) Cash, Beginning of Year 176,236 132,150 319,956 Cash, End of Year 122,381 $ 176,236 $ 132,150 Supplemental disclosure of cash flow information: Cash paid for income tax 21,273 $ 5,598 $ 222,026 Cash paid for interest 155,572 $ 151,335 $ 69,572 Supplemental disclosure of cash flow information: Right-of-use assets obtained in exchange for operating lease obligation 177,415 $ 66,419 $ 18,639
A12 藝術空間
OTC/Small Cap
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
